{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:41:09Z","timestamp":1792705269084,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03573-6","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:20:36Z","timestamp":1792704036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Polymorphic Transitions of Erlotinib Hydrochloride in PLGA Binary Mixtures: Influence of Polymer Functionality and Method of Crystallisation"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8802-0089","authenticated-orcid":false,"given":"Anumol","family":"Joseph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2371-3239","authenticated-orcid":false,"given":"Sideequl","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8970-7000","authenticated-orcid":false,"given":"Adarsh","family":"Malgave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0603-1492","authenticated-orcid":false,"given":"Ankit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8057-399X","authenticated-orcid":false,"given":"Ravichandiran","family":"Velayutham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1435-6115","authenticated-orcid":false,"given":"Rajkumar","family":"Malayandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"3573_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.addr.2003.10.008","volume":"56","author":"D Singhal","year":"2004","unstructured":"Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Deliv Rev. 2004;56:335\u201347. https:\/\/doi.org\/10.1016\/j.addr.2003.10.008.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"3573_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/ceat.200500397","volume":"29","author":"PH Karpinski","year":"2006","unstructured":"Karpinski PH. Polymorphism of active pharmaceutical ingredients. Chem Eng Technol. 2006;29(2):233\u20137. https:\/\/doi.org\/10.1002\/ceat.200500397.","journal-title":"Chem Eng Technol"},{"key":"3573_CR3","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s12045-009-0084-7","volume":"14","author":"R Purohit","year":"2009","unstructured":"Purohit R, Venugopalan P. Polymorphism: an overview. Resonance. 2009;14:882\u201393. https:\/\/doi.org\/10.1007\/s12045-009-0084-7.","journal-title":"Resonance"},{"key":"3573_CR4","doi-asserted-by":"publisher","first-page":"18759","DOI":"10.3390\/molecules201018759","volume":"20","author":"R Censi","year":"2015","unstructured":"Censi R, Martino PD. Polymorph impact on the bioavailability and stability of poorly soluble drugs. Molecules. 2015;20:18759\u201376. https:\/\/doi.org\/10.3390\/molecules201018759.","journal-title":"Molecules"},{"issue":"441","key":"3573_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics130404411","volume":"13","author":"M Banerjee","year":"2021","unstructured":"Banerjee M, Brettmann B. Stabilization of metastable indomethacin \u03b1 in cellulose nanocrystal aerogel scaffolds. Pharmaceutics. 2021;13(441):1\u201314. https:\/\/doi.org\/10.3390\/pharmaceutics130404411.","journal-title":"Pharamaceutics"},{"key":"3573_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrysgro.2026.128653","volume":"690","author":"GN Stoffan","year":"2026","unstructured":"Stoffan GN, Szabo-Tacsi K, Farkas A, Nagy ZK, Marosi G, Pataki H. New findings on the solvent-mediated polymorphic transformation of famotidine. J Cryst Growth. 2026;690:128653. https:\/\/doi.org\/10.1016\/j.jcrysgro.2026.128653.","journal-title":"J Cryst Growth"},{"key":"3573_CR7","doi-asserted-by":"publisher","first-page":"6562","DOI":"10.1039\/d4ce00863d","volume":"26","author":"T Li","year":"2024","unstructured":"Li T, Zhang J, Li M, Qu H, Wu S, Gong J. Mechanism of solvent-mediated polymorphic transformation to prepare axitinib form XLI controlled by water activity. CrystEngComm. 2024;26:6562\u201372. https:\/\/doi.org\/10.1039\/d4ce00863d.","journal-title":"CrystEngComm"},{"key":"3573_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17070946","volume":"17","author":"M Guerain","year":"2025","unstructured":"Guerain M, Willart JF. Polymorphic transformations of pharmaceutical materials induced by mechanical milling: a review. Pharmaceutics. 2025;17:946. https:\/\/doi.org\/10.3390\/pharmaceutics17070946.","journal-title":"Pharmaceutics"},{"key":"3573_CR9","unstructured":"ICH. Specifications: Tests procedures and acceptance criteria for new drug substances and new drug products: Chemical substances Q6A. Geneva, Switzerland; 1999."},{"key":"3573_CR10","doi-asserted-by":"publisher","unstructured":"Raw AS, Furness MS, Gill DS, Adams RC, Holcombe FO Jr, Yu LX. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). Adv Drug Deliv Rev. 2004;56:397\u2013414. https:\/\/doi.org\/10.1016\/j.addr.2003.10.011.","DOI":"10.1016\/j.addr.2003.10.011"},{"key":"3573_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116038","volume":"242","author":"JT Chambi","year":"2024","unstructured":"Chambi JT, Fandaruff C, Cuffini SL. Identification and quantification techniques of polymorphic forms - a review. J Pharm Biomed Anal. 2024;242:116038. https:\/\/doi.org\/10.1016\/j.jpba.2024.116038.","journal-title":"J Pharm Biomed Anal"},{"issue":"Supplement 6","key":"3573_CR12","doi-asserted-by":"publisher","first-page":"vi35","DOI":"10.1093\/annonc\/mdm222","volume":"18","author":"MA Bareschino","year":"2007","unstructured":"Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Erlotinib in cancer treatment. Ann Oncol. 2007;18(Supplement 6):vi35-41. https:\/\/doi.org\/10.1093\/annonc\/mdm222.","journal-title":"Ann Oncol"},{"key":"3573_CR13","doi-asserted-by":"publisher","unstructured":"Abdelgalil AA, Al-kahtani HM, Al-Jenoobi FI. Erlotinib. In: Profiles of drug substances, excipients and related methodology. 2020. p. 93\u2013117. https:\/\/doi.org\/10.1016\/bs.podrm.2019.10.004.","DOI":"10.1016\/bs.podrm.2019.10.004"},{"key":"3573_CR14","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1021\/je500482k","volume":"59","author":"J Lu","year":"2014","unstructured":"Lu J, Zhan X, Chen L, Zhang L, Mao S. Solubility of two polymorphs of erlotinib hydrochloride in isopropanol and acetone from (273.15 to 303.15) K. J Chem Eng Data. 2014;59:2665\u20139. https:\/\/doi.org\/10.1021\/je500482k.","journal-title":"J Chem Eng Data"},{"key":"3573_CR15","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1039\/d1ce00032b","volume":"23","author":"SH Thorat","year":"2021","unstructured":"Thorat SH, George CP, Shaligram PS, Suresha PR, Gonnade RG. Polymorphs and hydrates of the anticancer drug erlotinib: X-ray crystallography, phase transition and biopharmaceutical studies. CrystEngComm. 2021;23:3961\u201374. https:\/\/doi.org\/10.1039\/d1ce00032b.","journal-title":"CrystEngComm"},{"key":"3573_CR16","doi-asserted-by":"publisher","unstructured":"Selvanayagam S, Sridhar B, Ravikumar K. Erlotinib hydrochloride: an anticancer agent. Acta Crystallogr Sect E Struct Reports Online. 2008;E64(o931). https:\/\/doi.org\/10.1107\/S1600536808011707.","DOI":"10.1107\/S1600536808011707"},{"key":"3573_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.supflu.2010.06.009","volume":"55","author":"Y Tien","year":"2010","unstructured":"Tien Y, Su C, Lien L, Chen Y. Recrystallization of erlotinib hydrochloride and fulvestrant using supercritical antisolvent process. J Supercrit Fluids. 2010;55:292\u20139. https:\/\/doi.org\/10.1016\/j.supflu.2010.06.009.","journal-title":"J Supercrit Fluids"},{"issue":"2","key":"3573_CR18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.4337\/qmjip.2016.02.08","volume":"6","author":"E Ghosh","year":"2016","unstructured":"Ghosh E. A chapter called controversy: breaking down the Delhi high court appellate bench verdict in F Hoffmann-La Roche v Cipla Ltd. Queen Mary J Intellect Prop. 2016;6(2):260\u201372. https:\/\/doi.org\/10.4337\/qmjip.2016.02.08.","journal-title":"Queen Mary Journal of Intellectual Property"},{"issue":"1","key":"3573_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3978\/j.issn.2218-6751.2014.05.01","volume":"4","author":"BA Chan","year":"2015","unstructured":"Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl lung cancer Res. 2015;4(1):36\u201354. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2014.05.01.","journal-title":"Transl lung cancer Res"},{"key":"3573_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer ( EURTAC ): a multicentre , open-label , randomised phase 3 trial. Lancet Oncol. 2012;13:239\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(11)70393-X.","journal-title":"Lancet Oncol"},{"key":"3573_CR21","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00432-015-1935-0","volume":"141","author":"L Timmers","year":"2015","unstructured":"Timmers L, Boons CCLM, Hove JM, Smit EF, Van DPM, Aerts JG, et al. Adherence, exposure and patients \u2019 experiences with the use of erlotinib in non - small cell lung cancer. J Cancer Res Clin Oncol. 2015;141:1481\u201391. https:\/\/doi.org\/10.1007\/s00432-015-1935-0.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3573_CR22","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.2147\/ijn.s432464","volume":"18","author":"M Cong","year":"2023","unstructured":"Cong M, Pang H, Xie G, Li F, Li C, Sun H, et al. Engineering of amphiphilic erlotinib analogue as novel nanomedicine for non-small cell lung cancer therapy. Int J Nanomedicine. 2023;18:6367\u201377. https:\/\/doi.org\/10.2147\/ijn.s432464.","journal-title":"Int J Nanomedicine"},{"key":"3573_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s40005-019-00449-9","author":"W Young","year":"2019","unstructured":"Young W, Asadujjaman L, Jee JP. Long acting injectable formulations\u202f: the state of the arts and challenges of poly (lactic - co - glycolic acid) microsphere, hydrogel, organogel and liquid crystal. J Pharm Investig. 2019. https:\/\/doi.org\/10.1007\/s40005-019-00449-9.","journal-title":"J Pharm Investig"},{"issue":"2","key":"3573_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1615\/critrevtherdrugcarriersyst.v29.i2.20","volume":"29","author":"G Kumar","year":"2012","unstructured":"Kumar G, Shafiq N, Malhotra S. Drug-loaded PLGA nanoparticles for oral administration: fundamental issues and challenges ahead. Crit Rev Ther Drug Carrier Syst. 2012;29(2):149\u201382. https:\/\/doi.org\/10.1615\/critrevtherdrugcarriersyst.v29.i2.20.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"3573_CR25","doi-asserted-by":"publisher","unstructured":"Xu Y, Kim C soo, Saylor DM, Koo D. Polymer degradation and drug delivery in PLGA-based drug \u2013 polymer applications\u202f: A review of experiments and theories. J Biomed Mater Res - Part B. 2015;1\u201325. https:\/\/doi.org\/10.1002\/jbm.b.33648.","DOI":"10.1002\/jbm.b.33648"},{"key":"3573_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0169-409X(97)00049-5","volume":"28","author":"PBO Donnell","year":"1997","unstructured":"Donnell PBO, Mcginity JW. Preparation of microspheres by the solvent evaporation technique. Adv Drug Deliv Rev. 1997;28:25\u201342. https:\/\/doi.org\/10.1016\/S0169-409X(97)00049-5.","journal-title":"Adv Drug Deliv Rev"},{"issue":"14","key":"3573_CR27","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1080\/07373937.2021.1983823","volume":"40","author":"J Chakraborty","year":"2022","unstructured":"Chakraborty J, Subash M, Thorat BN. Drying induced polymorphic transformation of pharmaceutical ingredients\u202f: a critical review of recent progresses and challenges. Dry Technol. 2022;40(14):2817\u201335. https:\/\/doi.org\/10.1080\/07373937.2021.1983823.","journal-title":"Dry Technol"},{"key":"3573_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12060483","volume":"12","author":"C Asgreen","year":"2020","unstructured":"Asgreen C, Knopp MM, Skytte J, L\u00f6bmann K. Influence of the polymer glass transition temperature and molecular weight on drug amorphization kinetics using ball milling. Pharmaceutics. 2020;12:483. https:\/\/doi.org\/10.3390\/pharmaceutics12060483.","journal-title":"Pharmaceutics"},{"key":"3573_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejpb.2019.03.016","volume":"139","author":"C Zlomke","year":"2019","unstructured":"Zlomke C, Barth M, M\u00e4der K. Polymer degradation induced drug precipitation in PLGA implants \u2013 why less is sometimes more. Eur J Pharm Biopharm. 2019;139:142\u201352. https:\/\/doi.org\/10.1016\/j.ejpb.2019.03.016.","journal-title":"Eur J Pharm Biopharm"},{"issue":"993","key":"3573_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/polym14050993","volume":"14","author":"G Liu","year":"2022","unstructured":"Liu G, Mcennis K. Glass transition temperature of PLGA particles and the influence on drug delivery applications. Polymers (Basel). 2022;14(993):1\u201318. https:\/\/doi.org\/10.3390\/polym14050993.","journal-title":"Polymers (Basel)"},{"key":"3573_CR31","doi-asserted-by":"publisher","unstructured":"Godzo H, Deconinck E, Vanhee C, Waeytens J, Geskovski N, Gigopulu O, et al. ATR-FTIR spectroscopy coupled with multivariate analysis for monitoring degradation and secondary structure transitions in therapeutic peptide formulations. Spectrochim Acta Part A Mol Biomol Spectrosc. 2026;363. https:\/\/doi.org\/10.1016\/j.saa.2026.128280.","DOI":"10.1016\/j.saa.2026.128280"},{"key":"3573_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jpba.2016.01.035","volume":"122","author":"NL Calvo","year":"2016","unstructured":"Calvo NL, Kaufman TS, Maggio RM. Mebendazole crystal forms in tablet formulations . An ATR-FTIR \/ chemometrics approach to polymorph assignment. J Pharm Biomed Anal. 2016;122:157\u201365. https:\/\/doi.org\/10.1016\/j.jpba.2016.01.035.","journal-title":"J Pharm Biomed Anal"},{"key":"3573_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s42649-020-00032-9","author":"A Kumar","year":"2020","unstructured":"Kumar A, Singh P, Nanda A. Hot stage microscopy and its applications in pharmaceutical characterization. Appl Microsc. 2020. https:\/\/doi.org\/10.1186\/s42649-020-00032-9.","journal-title":"Appl Microsc"},{"key":"3573_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jics.2026.102613","volume":"103","author":"A Joseph","year":"2026","unstructured":"Joseph A, Akbar S, Malgave A, Suryawanshi R, Chhabra D, Malayandi R. Forced degradation study and impurity profiling of erlotinib hydrochloride using RP-HPLC and orbitrap LC-HRMS analysis and their in silico toxicity assessment. J Indian Chem Soc. 2026;103:1\u201318. https:\/\/doi.org\/10.1016\/j.jics.2026.102613.","journal-title":"J Indian Chem Soc"},{"key":"3573_CR35","unstructured":"Reddy P, Reddy R, Reddy R, Reddy M, Rao S. Erlotinib hydrochloride polymorph form A substantially free of polymorph form B. European Patent Application; 2010. Report No.: EP2218713A1."},{"key":"3573_CR36","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1021\/acs.jced.6b00796","volume":"62","author":"J Zhai","year":"2017","unstructured":"Zhai J, Zhao J, Chen Z, Xiao C, Liu X, Zhang L, et al. Solubility measurement and correlation of two erlotinib hydrochloride polymorphs in alcohols and ketones from 273.15 to 323.15 K. J Chem Eng Data. 2017;62:516\u201324. https:\/\/doi.org\/10.1021\/acs.jced.6b00796.","journal-title":"J Chem Eng Data"},{"issue":"1\u20132","key":"3573_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijpharm.2007.02.026","volume":"339","author":"JJ Rouse","year":"2007","unstructured":"Rouse JJ, Mohamed F, van der Walle CF. Physical ageing and thermal analysis of PLGA microspheres encapsulating protein or DNA. Int J Pharm. 2007;339(1\u20132):112\u201320. https:\/\/doi.org\/10.1016\/j.ijpharm.2007.02.026.","journal-title":"Int J Pharm"},{"key":"3573_CR38","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s13346-021-01013-5","volume":"12","author":"A Beig","year":"2022","unstructured":"Beig A, Feng L, Walker J, Ackermann R, Hong JKY, Li T, et al. Development and characterization of composition \u2011 equivalent formulations to the Sandostatin LAR \u00ae by the solvent evaporation method. Drug Deliv Transl Res. 2022;12:695\u2013707. https:\/\/doi.org\/10.1007\/s13346-021-01013-5.","journal-title":"Drug Deliv Transl Res"},{"key":"3573_CR39","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1021\/acs.cgd.3c00791","volume":"23","author":"CT Ant\u00f3nio","year":"2023","unstructured":"Ant\u00f3nio CT, \u00c9vora AOL, Bernardes CES, Diogo HP, Araujo GLBde, Smith P, et al. Polymorphism in erlotinib hydrochloride: new insights into relative stability , thermal behavior , and structural differences of forms A and B. Cryst Growth Des. 2023;23:7374\u201384. https:\/\/doi.org\/10.1021\/acs.cgd.3c00791.","journal-title":"Cryst Growth Des"},{"issue":"5","key":"3573_CR40","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/jps.22419","volume":"100","author":"D Grooff","year":"2011","unstructured":"Grooff D, Liebenberg W, Villiers MMDE. Preparation and transformation of true nifedipine polymorphs\u202f: investigated with differential scanning calorimetry and X-ray diffraction pattern fitting methods. J Pharm Sci. 2011;100(5):1944\u201357. https:\/\/doi.org\/10.1002\/jps.22419.","journal-title":"J Pharm Sci"},{"key":"3573_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ijpharm.2007.08.015","volume":"350","author":"C Mcgregor","year":"2008","unstructured":"Mcgregor C, Bines E. The use of high-speed differential scanning calorimetry (Hyper-DSC TM) in the study of pharmaceutical polymorphs. Int J Pharm. 2008;350:48\u201352. https:\/\/doi.org\/10.1016\/j.ijpharm.2007.08.015.","journal-title":"Int J Pharm"},{"key":"3573_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1039\/c2ce26448j","volume":"15","author":"JA Baird","year":"2013","unstructured":"Baird JA, Thomas LC, Aubuchon SR, Taylor LS. Evaluating the non-isothermal crystallization behavior of organic molecules from the undercooled melt state using rapid heat\/cool calorimetry. CrystEngComm. 2013;15:111\u20139. https:\/\/doi.org\/10.1039\/c2ce26448j.","journal-title":"CrystEngComm"},{"key":"3573_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0378-5173(99)00267-7","volume":"192","author":"E Verdonck","year":"1999","unstructured":"Verdonck E, Schaap K, Thomas LC. A discussion of the principles and applications of modulated temperature DSC ( MTDSC ). Int J Pharm. 1999;192:3\u201320. https:\/\/doi.org\/10.1016\/S0378-5173(99)00267-7.","journal-title":"Int J Pharm"},{"key":"3573_CR44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.tca.2006.02.008","volume":"443","author":"A Genovese","year":"2006","unstructured":"Genovese A, Amarasinghe G, Glewis M, Mainwaring D, Shanks RA. Crystallisation, melting, recrystallisation and polymorphism of n-eicosane for application as a phase change material. Thermochim Acta. 2006;443:235\u201344. https:\/\/doi.org\/10.1016\/j.tca.2006.02.008.","journal-title":"Thermochim Acta"},{"key":"3573_CR45","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1007\/s11095-013-1002-y","volume":"30","author":"CT John","year":"2013","unstructured":"John CT, Xu W, Lupton LK, Harmon PA. Formulating weakly basic HCl salts: relative ability of common excipients to induce disproportionation and the unique deleterious effects of magnesium stearate. Pharm Res. 2013;30:1628\u201341. https:\/\/doi.org\/10.1007\/s11095-013-1002-y.","journal-title":"Pharm Res"},{"key":"3573_CR46","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1021\/acs.molpharmaceut.2c01034","volume":"20","author":"DT Van","year":"2023","unstructured":"Van DT, Diab S, Hodnett NS, Taylor LS. Kinetic barriers to disproportionation of salts of weakly basic drugs. Mol Pharm. 2023;20:3886\u201394. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c01034.","journal-title":"Mol Pharm"},{"key":"3573_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.105200","author":"X Wang","year":"2024","unstructured":"Wang X, Cao J, Li Z, Xu R, Guo Y, Pu F, et al. Co-amorphous mixture of erlotinib hydrochloride and gallic acid for enhanced antitumor effects. J Drug Deliv Sci Technol. 2024. https:\/\/doi.org\/10.1016\/j.jddst.2023.105200.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3573_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-025-07692-12","volume":"15","author":"KPS Hussan","year":"2025","unstructured":"Hussan KPS, Babu TD, Thayyil MS, Sreeshma TS, Archana A. Physicochemical characterization and biological evaluation of amorphous solid dispersions of an anticancerous drug: Erlotinib HCl. Sci Rep. 2025;15:1\u201317. https:\/\/doi.org\/10.1038\/s41598-025-07692-12.","journal-title":"Sci Rep"},{"issue":"1","key":"3573_CR49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1139\/v60-003","volume":"38","author":"C Brissette","year":"2011","unstructured":"Brissette C, Sandorfy C. Hydrogen bonding in the amine hydrohalides. The infrared spectrum from 4000 to 2200 cm-1. Can J Chem. 2011;38(1):34\u201344. https:\/\/doi.org\/10.1139\/v60-003.","journal-title":"Can J Chem."},{"key":"3573_CR50","doi-asserted-by":"publisher","unstructured":"Erbetta CDC, Alves RJ, Resende JM, De RFSF, Sousa1 RG de. Synthesis and characterization of poly(D,L-Lactide-co-Glycolide) copolymer. J Biomater Nanobiotechnol. 2012;3:208\u201325. https:\/\/doi.org\/10.4236\/jbnb.2012.32027.","DOI":"10.4236\/jbnb.2012.32027"},{"issue":"1241","key":"3573_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/polym14061241","volume":"14","author":"S Jia","year":"2022","unstructured":"Jia S, Ning S, Leng Y, Jing Q, Xu Z, Ren F. Stabilizing effect of soluplus on erlotinib metastable crystal form in microparticles and amorphous solid dispersions. Polymers (Basel). 2022;14(1241):1\u201313. https:\/\/doi.org\/10.3390\/polym14061241.","journal-title":"Polymers (Basel)"},{"key":"3573_CR52","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00598-6","author":"DE Moseson","year":"2021","unstructured":"Moseson DE, Corum ID, Lust A, Altman KJ, Hiew TN, Nagy ZK, et al. Amorphous solid dispersions containing residual crystallinity\u202f: competition between dissolution and matrix crystallization. AAPS J. 2021. https:\/\/doi.org\/10.1208\/s12248-021-00598-6.","journal-title":"AAPS J"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03573-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03573-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03573-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:20:38Z","timestamp":1792704038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03573-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":52,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3573"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03573-6","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"13 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"333"}}